Identifying Potential Drug Targets for Varicose Veins through Integration of GWAS and eQTL Summary Data

Yu Cui; Mengting Hu; He Zhou; Jiarui Guo; Qijia Wang; Zaihua Xu; Liyun Chen; Wancong Zhang; Shijie Tang

doi:10.1101/2024.01.27.24301809

Abstract

Background Varicose veins (VV) is a common chronic venous disease that is influenced by multiple factors. It affects the quality of life of patients and imposes a huge economic burden on the healthcare system. This study aimed to use integrated analysis methods, including Mendelian randomization analysis, to identify potential pathogenic genes and drug targets for VV treatment.

Methods This study conducted summary-data-based Mendelian randomization (SMR) analysis and colocalization analysis on data collected from genome-wide association studies (GWASs) and cis-expression quantitative trait loci (cis-eQTL) databases. Only genes with PP. H4 > 0.7 were chosen from the significant SMR results. After the above analysis, we screened 12 genes and performed Mendelian Randomization analysis on them. After sensitivity analysis, we identified four genes with potential causal relationships with VV. Finally, we used transcriptome-wide association studies (TWAS) analysis and The Drug-Gene Interaction Database (DGIdb, https://dgidb.org)data to identify and screen the remaining genes and identified four drug targets for the treatment of VV.

Results We identified four genes significantly associated with VV, namely KRTAP5-AS1 (OR = 1.08, 95% CI: 1.05−1.11, p = 1.42e−10) and PLEKHA5 (OR = 1.13, 95% CI: 1.06-1.20, p = 6.90e−5), CBWD1 (OR = 1.05, 95% CI: 1.01-1.11, p = 1.42e−2) and CRIM1 (OR = 0.87, 95% CI: 0.81-0.95, p = 3.67e−3). Increased expression of three genes, namely KRTAP5-AS1, PLEKHA5, and CBWD1, was associated with increased risk of the disease, and increased expression of CRIM1 was associated with decreased risk of the disease. These four genes could be targeted for VV therapy.

Conclusion This study identified four drug targets for potential treatment of VV, and the results may contribute to improving the quality of life of VV patients.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by the Guangdong Basic and Applied Basic Research Foundation (2019A1515011857, 2021A1515011142, 2023A1515012343, 2022A1515220099), Guangdong University Innovation Team Project (2021KCXTD047), Provincial science and technology innovation strategy special project funding program (200114165897946, 210714106901245, STKJ202209067, STKJ2023004), 2022 Shantou University Graduated Student Innovation Program (Shandafa[2022]207)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used (or will use) ONLY openly available human data that were originally located at Genotype-Tissue Expression, UK BioBank, Finngen biobank and eQTLGen Consortium.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced are available online from each genome-wide association study.

https://gwas.mrcieu.ac.uk/datasets/ukb-b-6720/

https://yanglab.westlake.edu.cn/data/SMR/GTEx_V8_cis_eqtl_summary.html

https://www.eqtlgen.org/cis-eqtls.html

https://storage.googleapis.com/finngen-public-data-r9/summary_stats/finngen_R9_I9_VARICVE.gz

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.